GSK Stock Jumps As 3 Biotech Names Gain From Its R And D Reset

GSK's announcement of a £1.9 billion cost-cutting program and renewed investment in UK life sciences has led to a 6% stock jump. This strategic shift, focusing on later-stage drug development, is expected to benefit companies like Alnylam Pharmaceuticals, Repligen, and Ligand Pharmaceuticals. These three biotech firms are seen as favorably positioned due to their alignment with GSK's R&D priorities, offering exposure to advanced therapeutic development and royalty streams.